Removing Lymph Nodes During Kidney Surgery for High-Risk Upper Urinary Tract Cancer

Trial details

Who runs it

Tianjin Medical University Second Hospital

Trial code

NCT07321210

Record updated

25 June 2026

Original description

The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are:Read full original descriptionShow less

Clinical Efficacy and Safety of Radical Nephroureterectomy With Versus Without Template Lymph Node Dissection in High-Risk Upper Tract Urothelial Carcinoma: A Multicenter, Prospective, Randomized Controlled Clinical Trial

The goal of this clinical trial is to learn if adding a template lymph node dissection (TLND) to the standard surgery for upper tract urothelial cancer (UTUC) can improve patient survival and prevent the cancer from recurrence. The main questions it aims to answer are:

Do patients who receive standard surgery with LND live longer without their cancer returning? Is adding LND safe, and how does it affect surgery-related complications? Researchers will compare the group receiving standard surgery plus LND to the group receiving standard surgery alone to see if adding LND is more effective.

Participants will:

Be randomly assigned to one of the two surgical groups. Undergo their assigned surgery and recover in the hospital. Attend regular follow-up visits for checkups and scans for 5 years to monitor for cancer recurrence, with the possibility of long-term follow-up extending to 10 years.

Inclusion: Signed written informed consent form (ICF); Age > 18 years at the time of ICF signing; Clinical diagnosis of unilateral Upper Tract Urothelial Carcinoma (UTUC) by imaging (enhanced CT or MRI) and/or ureteroscopic biopsy/urinary cytology, and scheduled to undergo Radical Nephroureterectomy (RNU); Clinical assessment indicating that the tumor and regional lymph nodes are completely resectable, with at least one of the following high-risk features:; Locally advanced: Preoperative imaging assessed as cT2 stage or higher (i.e., tumor invades muscularis propria or deeper); High-grade: Preoperative ureteroscopic biopsy pathology confirmed as high-grade urothelial carcinoma (or with squamous differentiation/sarcomatoid differentiation); Moderate or severe hydronephrosis: Ipsilateral moderate or severe hydronephrosis due to tumor obstruction; Large tumor size: Imaging measures maximum tumor diameter > 2 cm; cN1: Imaging suggests regional lymph node short-axis diameter > 1 cm, and the investigator judges it to be resectable; Presence of at least one measurable lesion according to RECIST v1.1 criteria; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Adequate organ function meeting the following requirements (without use of any blood components or colony-stimulating factors within 14 days):; Bone marrow function: Neutrophils ≥ 1,500/mm³, Platelets ≥ 100,000/mm³, Hemoglobin ≥ 9 g/dL (5.6 mmol/L); Renal function: Serum creatinine ≤ 1.5 mg/dL and/or Creatinine clearance ≥ 60 mL/min; Liver function: Total bilirubin ≤ 1.5 × ULN, AST \& ALT ≤ 1.5 × ULN; For women of childbearing potential (WOCBP): Must agree to use a highly effective medically approved contraceptive method during the treatment period and for 3 months after treatment ends. A negative serum or urine pregnancy test within 7 days before enrollment is required; must be non-lactating. For non-sterilized male patients: Must agree to use effective contraception with their partner during the treatment period and for 3 months after treatment ends; Subject voluntarily joins the study, has good compliance, and agrees to undergo safety and survival follow-up.

Exclusion: Previous receipt of any anti-tumor therapy for UTUC, including chemotherapy, radiotherapy, immunotherapy, or targeted therapy; History or concurrent presence of muscle-invasive bladder urothelial carcinoma; Current use of immunosuppressants for immunosuppressive purposes, continued within 2 weeks prior to enrollment; Occurrence of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to surgery; Participation in another clinical study within 1 month prior to enrollment, or potential receipt of other systemic anti-tumor therapy during the study period; Known bilateral UTUC or hereditary diseases that definitively increase the risk of contralateral upper tract tumors, such as Lynch Syndrome; Diagnosis of other active malignancies within the past 5 years (except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix which have been cured and show no recurrence within 5 years); Presence of any active autoimmune disease or history of autoimmune disease; Poorly controlled cardiac clinical symptoms or diseases; Coagulation abnormalities or bleeding tendency; Presence of specific active gastrointestinal conditions or uncontrolled tumor bleeding; History of significant bleeding, hemoptysis, or thromboembolic events within specified timeframes; Active infection or unexplained fever > 38.5°C during screening or before the first dose; History or current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severely impaired pulmonary function, etc; Known history of psychotropic drug abuse, alcohol abuse, or drug use; Any other condition deemed by the investigator to make the subject unsuitable for participation; Preoperative imaging assesses regional lymph nodes as unresectable: lymph nodes fused into a massive conglomerate, or fully encasing the abdominal aorta/inferior vena cava/pelvic vessels preventing safe separation; Congenital or acquired immunodeficiency; Inability or unwillingness to bear the out-of-pocket costs of examinations and treatments.

ClinicalTrials.gov NCT07321210